NL-OMON54315招募中不适用
Glioblastoma targeted treatment option maximization by WGS (GLOW);Maximizing treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics - GLOW
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 235
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histopathologically confirmed IDH wild type glioblastoma, first recurrence
- •after standard chemoradiation; suitable for standard-of-care re-resection or
- •2. Age >= 18 years;
- •3. Able and willing to give written informed consent;
- •4. Life expectancy >3 months, allowing adequate follow-up of toxicity
- •evaluation and antitumor activity;
- •5. KPS performance status >=70;
- •6. Deemed eligible for targeted treatment options.
排除标准
- •1. Currently actively treated in another antitumor clinical trial (excluding
- •DRUP and STELLAR studies);
- •2. Patients with any other clinically significant medical condition which, in
- •the opinion of the treating physician, makes it undesirable for the patient to
- •participate in medication studies or which could jeopardize compliance with
- •study requirements including, but not limited to ongoing or active infection,
- •significant uncontrolled hypertension, or severe psychiatric illness/social
- •situations.
研究者
相似试验
招募中
3 期
Glioblastoma, Optimizing Logistics and Dose (GOLD).glioblastoma10029211brain tumorNL-OMON52680niversitair Medisch Centrum Utrecht474
进行中（未招募）
1 期
Study to evaluate the potentiation effect of radiotherapy by AGuIX nanoparticles for the treatment of persistent glioblastomaPersistent Glioblastoma Multiforme, grade IVMedDRA version: 20.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-003774-32-ITDIPARTIMENTO BIOMEDICINA E PREVENZIONE UNIVERSITà DEGLI STUDI DI ROMA TOR VERGATA30
进行中（未招募）
不适用
First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells - GBM-VaxPatients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiation therapy and standard chemotherapy with temozolomide.MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-015979-27-ATActivartis Biotech GmbH76
进行中（未招募）
不适用
First Line Therapy of Glioblastoma Multiforme with Surgical Resection, Irradiation Therapy, Temozolomide and Additional Tumour-Lysate Pulsed Dendritic Cell Vaccination. A Feasibility Phase II Study. - NAGlioblastoma MultiformeEUCTR2009-013406-13-CZMasaryk University
Unknown
不适用
Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine ModelGlioblastomaNCT02904525Andreas Hottinger20